Gilead is looking for another shot at treating rheumatoid arthritis after its massive Galapagos deal fell flat in the face of an FDA rejection and, more recently, a withdrawn Phase I of another asset for the inflammatory disease.
The California biopharma, coming off a strong finish to 2022 with an...
